Glycogen synthase kinase 3 (GSK-3) is a serine/threonine kinase with key roles in myriad biological processes, such as tumor progression, and inhibition of GSK-3 using novel small-molecule elraglusib has shown promising preclinical antitumor activity in multiple tumor types [1]. The gene discussed is MARK2; the disease is neoplasm.